David Robertson, MD
Surgery · Lancaster, OHNPI 1811983067
Payments from drug & device makers
Across 57 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$280
- TELA Bio, Inc.$79
- Takeda Pharmaceuticals U.S.A., Inc.$71
- AbbVie$69
- Pacira Pharmaceuticals Incorporated$65
- Tetraphase Pharmaceuticals, Inc.$52
- plus $400 from 21 others
What the payments were for
- Food & beverage$1,015100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 16 | $280 |
| TELA Bio, Inc. | 5 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| AbbVie(2 entities) | 4 | $69 |
| Pacira Pharmaceuticals Incorporated | 3 | $65 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $52 |
| AstraZeneca | 2 | $31 |
| Astellas Pharma US Inc | 1 | $29 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Medtronic | 1 | $25 |
| Bard Peripheral Vascular, Inc. | 1 | $25 |
| Innocoll Pharmaceuticals Limited | 1 | $24 |
| Sanara Medtech Inc. | 1 | $23 |
| La Jolla Pharmaceutical Company | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Edwards Lifesciences | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $19 |
| Davol Inc. | 1 | $19 |
| Intuitive Surgical | 2 | $17 |
| KCI USA, Inc. | 1 | $15 |
| Bioptics, Inc. | 1 | $14 |
| Checkpoint Surgical, Inc | 1 | $13 |
| Convatec Inc. | 1 | $13 |
| Covidien LP | 1 | $13 |
| Smith+Nephew | 1 | $12 |
| Osiris Therapeutics Inc. | 1 | $12 |
| Ferring Pharmaceuticals Inc. | 1 | $11 |
How this compares
$1,015 in reported general payments places this provider in the 40th percentile of 988 surgery providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 106 | $1,862 |
| Sucralfate | 33 | $1,325 |
| Omeprazole | 76 | $1,220 |
| Tamoxifen Citrate | 24 | $1,120 |
| Famotidine | 15 | $313 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 67 | $309 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $136 |
Paid to pharmacies, not to this prescriber.
Other surgery in Lancaster
- Jeffrey YencharLancaster$105K
- Jonathan ThompsonWest Chester$2.2M
- Raymond OndersCleveland$1.2M
- Clayton PetroCleveland$1.1M
- Ali AminianCleveland$1.1M
- Michael RosenCleveland$983K
- Michael MearaColumbus$868K
- Neilendu KunduCleveland$808K
- Chase WehrleCleveland$741K
- Ihya GorgunCleveland$704K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.